May 5, 2010 — A potential role for histaminergic neurotransmission has been identified in the condition underlying Tourette's syndrome and nervous tics, according to the findings of a genetic analysis published online May 5 in the New England Journal of Medicine."This is the first observation of a link between histaminergic neurotransmission and tics in humans and one of the few times that a clearly functional coding mutation has been found in a family with Tourette's syndrome," said the study's principal investigator Matthew W. State, MD, PhD, with the Yale Child Study Center in New Haven, Connecticut.
"Given the availability of pharmacological agents that specifically increase histaminergic neurotransmission, the finding suggests a novel approach to treating Tourette's syndrome," he told Medscape Neurology.
According to the researchers, Tourette's syndrome has a population prevalence of 1% and a rate of recurrence of 10% to 15% among first-degree relatives of an affected person. Although a genetic contribution to Tourette's syndrome is well established, thus far, findings have been nonreproducible.
More at at
http://www.medscape.com/viewarticle/721234">MEDSCAPE and
http://content.nejm.org/cgi/content/full/NEJMoa0907006">NEJM